bms-708163 + midazolam + warfarin + caffeine + omeprazole + dextromethorphan

**This drug is a combination of six agents:**\n- **BMS-708163 (Avagacestat):** A potent, selective, Notch-sparing γ-secretase inhibitor developed for Alzheimer’s disease. Its mechanism is selective inhibition of amyloid precursor protein (APP) cleavage to amyloid-β (Aβ), with >100-fold selectivity for APP versus Notch[1][2][3][7][9][5].\n- **Midazolam:** A benzodiazepine acting as a positive allosteric modulator of the GABA-A receptor, indicated primarily as a sedative/anxiolytic and for anesthesia induction.\n- **Warfarin:** An oral anticoagulant that inhibits vitamin K epoxide reductase, used to prevent and treat thromboembolic disease.\n- **Caffeine:** A xanthine derivative and central nervous system stimulant, acting mainly as an adenosine receptor antagonist, with additional effects on phosphodiesterase inhibition.\n- **Omeprazole:** A proton pump inhibitor that inhibits the gastric H+/K+ ATPase, indicated for peptic ulcer disease and gastroesophageal reflux disease.\n- **Dextromethorphan:** A cough suppressant acting as an NMDA receptor antagonist, sigma-1 receptor agonist, and serotonin reuptake inhibitor.\n\nThis combination appears to be a multi-agent formulation, likely assembled for drug-drug interaction studies, rather than for direct therapeutic use.

Brand names

Avagacestat

Other names

BMS-708163BMS708163BMS 708163Avagacestat